share_log

Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient

Red Light Holland 開始對迷幻藥松露進行實驗研究,以開發天然來源活性藥物成分的商業製造工藝
newsfile ·  03/08 21:05

Toronto, Ontario--(Newsfile Corp. - March 8, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has initiated an experimental research project to develop a process for the commercial manufacture of natural-source Active Pharmaceutical Ingredient (API) derived from the Company's psilocybin truffles.

安大略省多倫多--(Newsfile Corp.,2024 年 3 月 8 日)——Red Light Holland Corp.(CSE:TRIP)(FSE:4YX)(OTCQB:TRUFF)(”荷蘭紅燈“或者”公司“)是一家在北美和歐洲生產、種植和銷售功能性蘑菇和蘑菇家用種植套件的公司,也是向荷蘭合法娛樂市場銷售優質迷幻藥松露品牌的公司,很高興地宣佈,它已經啓動了一項實驗研究項目,以開發一種源自該公司迷幻藥松露的天然活性藥物成分(API)的商業生產工藝。

"While we have seen excellent movement in a number of emerging markets, it has become clear that there is also a demand for a range of medical products based off of Psilocybin mushrooms and truffles and optionality is key in our two-pronged approach," said Todd Shapiro, CEO and Director of Red Light Holland. "With the development of a process to manufacture natural-source Psilocybin API, we believe that Red Light Holland will be able to produce high-margin Psilocybin medical products - and gain valuable intellectual property."

Red Light Holland首席執行官兼董事託德·夏皮羅表示:“儘管我們在許多新興市場看到了良好的發展,但很明顯,對一系列基於迷幻藥蘑菇和松露的醫療產品的需求也很明顯,可選性是我們雙管齊下的關鍵。”“通過開發一種生產天然來源的迷幻藥原料藥的工藝,我們相信Red Light Holland將能夠生產高利潤的迷幻藥醫療產品,並獲得寶貴的知識產權。”

The project will be managed by researchers from PharmAla Biotech (CSE: MDMA) (OTCQB: MDXXF) and should yield a process for the extraction and subsequent purification of Psilocybin into a form such that it can be formulated into medical products for use in a variety of markets. Psilocybin truffles imported under Red Light Holland's previously-announced 5kg import through CCrest Labs will serve as starting material for the process development. The process should be specific and standardized such that it can be transferred into a variety of contract manufacturing facilities, enabling full-scale GMP manufacturing.

該項目將由來自Pharmala Biotech(CSE:MDMA)(OTCQB:MDXF)的研究人員管理,並應提供一種將迷幻藥提取並隨後純化爲可以配製成用於各種市場的醫療產品的方法。紅燈荷蘭先前宣佈通過CCrest實驗室進口的5千克松露進口的迷幻藥松露將作爲工藝開發的起始材料。該過程應具體且標準化,以便可以將其轉移到各種合同製造設施中,從而實現全面的GMP製造。

"As we move towards regulated therapeutic psilocybin markets in countries like Australia, we continue to believe that a high-quality natural source of API is of significant value," said Nick Kadysh, CEO, PharmAla Biotech. "We are happy to work on behalf of Red Light Holland to execute this process development work."

PharMala Biotech首席執行官尼克·卡迪什表示:“隨着我們在澳大利亞等國家向受監管的治療性迷幻藥市場邁進,我們仍然認爲高質量的原料藥天然來源具有重大價值。”“我們很高興代表Red Light Holland合作執行這項流程開發工作。”

About PharmAla

關於 Pharmala

PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a "regulatory first" organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

PharMala Biotech Holdings Inc.是一家生物技術公司,專注於研究、開發和製造包括****在內的MDX類分子。PharMala的創立有兩個重點:緩解全球積壓的仿製藥臨床級****,以便在特定司法管轄區進行臨床試驗和商業銷售,以及開發同類新藥。PharMala是目前唯一一家爲臨床試驗以外的患者治療提供臨床級****的公司。PharMala 的研發部門已經完成了對多個知識產權家族的概念驗證研究,包括其主要候選藥物 ALA-002。PharMala是一個 “監管第一” 組織,成立的原則是,迷幻藥行業的真正成功只能通過與監管機構的良好關係才能實現。

About Red Light Holland
The Company is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

荷蘭紅光簡介
該公司是一家總部位於安大略省的公司,根據所有適用法律,在北美和歐洲生產、種植和銷售功能性蘑菇和蘑菇家用種植套件,並向荷蘭境內的合法娛樂市場銷售優質品牌的迷幻藥松露。

For additional information:

欲了解更多信息:

Todd Shapiro
Chief Executive Officer and Director Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website:

託德·夏皮羅
首席執行官兼董事電話:647-643-TRIP (8747)
電子郵件:todd@redlight.co
網站:

Cautionary Statement Regarding Forward-Looking Statements

關於前瞻性陳述的警示聲明

This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.

本新聞稿包含適用的加拿大證券立法所指的某些 “前瞻性信息”。此類前瞻性信息和前瞻性陳述不代表歷史事實或信息或當前狀況,而僅代表公司對未來事件、計劃或目標的信念,其中許多信念本質上是不確定的,不在公司的控制範圍內。通常,但並非總是如此,前瞻性陳述和信息可以通過使用 “計劃”、“預期” 或 “不期望”、“預期”、“估計”、“打算”、“預期” 或 “不相信” 等詞語來識別,或此類詞語和短語的變體,或聲明某些行動、事件或結果 “可能”、“會”、“可能” 或 “可能” 或 “將” 被採取、發生或實現。

Forward-looking statements in this news release include statements relating to: as a result of the research, the Company will be able to produce high-margin Psilocybin medical products and gain valuable intellectual property; the research will yield a process for the extraction and subsequent purification of Psilocybin into a form such that it can be formulated into medical products for use in a variety of markets; the Company's 5kg import through CCrest Labs will serve as starting material for the process development; the development process can be transferred into a variety of contract manufacturing facilities, enabling full-scale GMP manufacturing; and the belief that that a high-quality natural source of API is of significant value.

本新聞稿中的前瞻性陳述包括與以下內容相關的陳述:通過研究,公司將能夠生產高利潤的迷幻藥醫療產品並獲得寶貴的知識產權;該研究將產生一種將迷幻藥提取並隨後純化成可以配製成用於各種市場的醫療產品的工藝;該公司通過CCrest Labs進口的5千克將作爲工藝開發的起始材料; 開發過程可以轉移轉化爲各種合同製造設施,實現全面的GMP製造;並堅信高質量的原料藥天然來源具有重大價值。

Forward-looking information in this press release are based on certain assumptions and expected future events, namely: the Company's ability to carry out the research; the research will achieve the stated goals; the starting research material remains suitable for the Company's research; the development process can be transferred into a variety of contract manufacturing facilities, enabling full-scale GMP manufacturing; and the realization of the belief that that a high-quality natural source of API is of significant value.

本新聞稿中的前瞻性信息基於某些假設和預期的未來事件,即:公司開展研究的能力;研究將實現既定目標;起始研究材料仍然適合公司的研究;開發過程可以轉移到各種合同製造設施,從而實現全面的GMP製造;以及實現高質量原料藥天然來源具有重要價值的信念的實現。

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company's inability to carry out the research; the research will not achieve the stated goals; the starting research material becoming unsuitable for the Company's research; the development process will not be transferrable into a variety of contract manufacturing facilities, and not enabling full-scale GMP manufacturing; and that high-quality natural source of API does not become of significant value.

這些陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果、業績或成就與此類陳述所表達或暗示的存在重大差異,包括但不限於:公司無法進行研究;研究無法實現既定目標;起始研究材料不適合公司的研究;開發過程將無法轉移到各種合同製造設施,也無法實現全面發展 GMP製造;而且高質量的原料藥天然來源不會具有重大價值。

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

提醒讀者,上述列表並不詳盡。進一步提醒讀者不要過分依賴前瞻性陳述,因爲無法保證這些陳述所依據的計劃、意圖或期望會實現。此類信息雖然在準備時被管理層認爲是合理的,但可能被證明是不正確的,實際結果可能與預期的結果存在重大差異。

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements.

儘管公司認爲準備前瞻性信息和陳述時使用的假設和因素以及其中包含的預期是合理的,但不應過分依賴此類信息和陳述,也不能保證或保證此類前瞻性信息和陳述將被證明是準確的,因爲實際結果和未來事件可能與此類信息和陳述中的預期存在重大差異。

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

本新聞稿中包含的前瞻性信息和前瞻性陳述自本新聞稿發佈之日起作出,除非根據適用的證券法,否則公司不承諾更新此處包含或引用的任何前瞻性信息和/或前瞻性陳述。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論